Compare RKT & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RKT | IQV |
|---|---|---|
| Founded | 1985 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Finance: Consumer Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 43.1B |
| IPO Year | 2020 | 2013 |
| Metric | RKT | IQV |
|---|---|---|
| Price | $13.19 | $269.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 16 |
| Target Price | $20.40 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 20.5M | 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | 0.19 | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $66.40 | $6.77 |
| Revenue Next Year | $8.18 | $5.89 |
| P/E Ratio | ★ $69.37 | $162.59 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $12.17 | $154.50 |
| 52 Week High | $24.36 | $271.80 |
| Indicator | RKT | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 65.29 |
| Support Level | $12.37 | $159.91 |
| Resistance Level | $14.61 | $271.80 |
| Average True Range (ATR) | 0.49 | 6.15 |
| MACD | -0.07 | -1.48 |
| Stochastic Oscillator | 21.00 | 69.82 |
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.